Rest Of Europe CAR T-Cell Therapy Market (2026-2031)
The Rest Of Europe CAR T-Cell Therapy Market was valued at $22.1 Million in 2026 and projected to reach to $33.3 Million by 2031, representing a compound annual growth rate of 8.5%. Rest Of Europe represents a significant emerging market for CAR T-cell therapy, characterized by steady growth momentum and increasing healthcare modernization.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
Rest Of Europe CAR T-Cell Therapy Market Trends and Insights
- The region is poised for steady growth, projected to reach $33.3 million by 2031, driven by increasing adoption of advanced immunotherapies and expanding healthcare infrastructure across Rest Of Europe.
- Rest Of Europe's growth trajectory reflects rising investment in oncology treatments and growing patient awareness of cellular therapies. The CAR T-cell therapy market in Rest Of Europe is characterized by gradual market penetration and regulatory harmonization efforts.
- Rest Of Europe is experiencing increased clinical trial activity and manufacturing capacity development, supporting the 8.5% compound annual growth rate through 2031.
- Rest Of Europe's healthcare systems are progressively integrating CAR T-cell therapies into treatment protocols, though adoption rates remain lower than Western European markets, presenting substantial long-term growth opportunities..
Key Market Statistics
- CAGR (2026-2031) 8.5% CAGR
- Market Size, 2026 ~USD 22.1 Million
- Forecast, 2031 ~USD 33.3 Million
- Country Rest Of Europe
Rest Of Europe CAR T-Cell Therapy Market Overview
Market Size Growth :
Rest Of Europe's CAR T-cell therapy market is estimated at $22.1 million in 2026, expanding to $33.3 million by 2031, representing a robust 8.5% CAGR over the forecast period.
Healthcare Infrastructure Expansion :
Increasing investment in advanced immunotherapy infrastructure across Rest Of Europe is driving market adoption, with emerging economies strengthening their oncology treatment capabilities.
Immunotherapy Adoption Trends :
Rising clinical adoption of CAR T-cell therapies in Rest Of Europe reflects growing physician awareness and patient demand for innovative cancer treatment options beyond traditional chemotherapy.
Regulatory and Reimbursement Progress :
Improving regulatory pathways and expanding reimbursement coverage in Rest Of Europe countries are facilitating faster market penetration and accessibility of CAR T-cell therapies.
Rest Of Europe CAR T-Cell Therapy Market Dynamics
- The region's market expansion is driven by rising investment in advanced immunotherapies, growing oncology patient populations, and strengthening healthcare infrastructure across multiple countries.
- Adoption rates are accelerating as healthcare systems recognize the clinical benefits of CAR T-cell treatments for hematologic malignancies. The forecast period through 2031 indicates sustained growth potential for Rest Of Europe, supported by improving reimbursement frameworks, expanding clinical trial activities, and increasing physician expertise in cell therapy administration.
- Market players are strategically positioning themselves to capture emerging opportunities as healthcare budgets allocate greater resources toward precision medicine and advanced immunotherapies in the region..
Related Ecosystem
Biotechnology
- Reagents
- Polymerase Chain Reaction (PCR)
- Stem Cells
- Assay Kits
- Flow Cytometers
- Thermo Fisher Scientific Inc.
- Merck KGaA
- Danaher Corporation
- Agilent Technologies, Inc.
- Bio-Rad Laboratories, Inc.
Pharmaceuticals
- Bioreactors
- Analytical Testing
- Bioanalytical Testing Services
- Cell Counters
- Data Management Services
- Merck KGaA
- Thermo Fisher Scientific Inc.
- SANOFI
- NOVARTIS
- Pfizer Inc.
Key Takeaways
- Rest Of Europe's CAR T-cell therapy market is valued at $22.1 million in 2026 and will grow to $33.3 million by 2031 at an 8.5% CAGR.
- Rest Of Europe demonstrates slower adoption compared to Western Europe, but offers significant untapped potential for market expansion.
- Rest Of Europe is investing in manufacturing infrastructure and clinical capabilities to support CAR T-cell therapy accessibility.
- Rest Of Europe's regulatory environment is evolving to facilitate faster approval and reimbursement of advanced cellular therapies.
CAR T-Cell Therapy Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2026 |
| Fastest Growing Segment | CD19/20 (Target) |
| Forecast Period | 2026–2031 |
| Growth Rate | CAGR of 13.7% from 2026 to 2031 |
| Largest Segment | CD19 (Target) |
| Market Size Base Year (Billions) | ~USD 7.25 (2026) |
| Revenue Forecast (Billions) | ~USD 13.78 (2031) |
| Segments Covered | Product, Target, Indication |
Rest Of Europe CAR T-Cell Therapy Market Report Segmentation
3 segment dimensions are covered across the global market.
By Product
- Abecma
- Breyanzi
- Carvykti
- Kymriah
- Other Products
- Tecartus
- Yescarta
By Target
- Bcma
- Cd19
- Cd19/20
- Cd7
- Other Targets
By Indication
- Acute Lymphoblastic Leukemia (All)
- B-Cell Lymphoma (Bcl)
- Multiple Myeloma
- Other Indications
Target Audience
- Pharmaceutical & Biotech Companies : Manufacturers and developers of CAR T-cell therapies need Rest Of Europe market data to evaluate commercial viability, plan market entry strategies, and allocate R&D resources effectively.
- Healthcare Investment Firms : Private equity and venture capital investors require detailed Rest Of Europe market forecasts and growth drivers to assess investment opportunities and portfolio company valuations.
- Hospital & Treatment Centers : Oncology centers and healthcare institutions in Rest Of Europe need market insights to plan CAR T-cell therapy program development, infrastructure investments, and patient care capabilities.
- Medical Device & Diagnostics Suppliers : Companies providing supporting technologies and diagnostics require Rest Of Europe market intelligence to identify partnership opportunities and develop complementary solutions.
- Healthcare Policy & Regulatory Bodies : Government agencies and health authorities in Rest Of Europe need market analysis to inform reimbursement policies, regulatory frameworks, and healthcare resource allocation decisions.
Key Companies in the Rest Of Europe CAR T-Cell Therapy Market
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| JOHNSON & JOHNSON | United States | Public Company | Oncology and Immunology (Innovative Medicine),Neuroscience, Cardiovascular & Metabolism, Pulmonary Hypertension, Infectious Diseases,Surgery and Interventional (instrumentation, energy, stapling, wound closure, biosurgery, robotic and digital), |
| GILEAD SCIENCES, INC. | United States | Public Company | HIV portfolio (Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, Yeztugo),Liver disease and other antivirals (Epclusa, Livdelzi, Vemlidy, AmBisome),COVID-19 (Veklury), |
| BRISTOL-MYERS SQUIBB COMPANY | United States | Public Company | Eliquis (anticoagulation),Immuno-oncology (Opdivo, Yervoy, Opdualag, Opdivo Qvantig),Hematology (Revlimid, Pomalyst/Imnovid, Reblozyl, Abecma, Breyanzi), |
| NOVARTIS AG | Switzerland | Public Company | Oncology & Hematology (Kisqali, Tafinlar+Mekinist, Jakavi, Pluvicto, Lutathera, Scemblix, Fabhalta),Immunology & Neuroscience (Cosentyx, Xolair, Ilaris, neurology assets),Cardiovascular, Renal & Metabolic (Entresto, Leqvio, other CVRM), |
| AUTOLUS THERAPEUTICS | United Kingdom | Public Company | CD19 CAR-T franchise (AUCATZYL / obe-cel – oncology),Autoimmune CD19 programs (obe-cel in SLE, MS, lupus nephritis),Next-generation oncology pipeline (AUTO1/22, AUTO8, AUTO6NG), |
| JW (CAYMAN) THERAPEUTICS CO., LTD. | China | Public Company | Commercial and late-stage CAR-T for hematologic malignancies (Carteyva, JWCAR201, JWCAR239),Autoimmune indications (relma-cel for SLE and related programs),Solid tumor pipeline (JWATM204/214/203/213, JWTCR001, JWCAR031), |
| CARSGEN THERAPEUTICS HOLDINGS LIMITED | China | Public Company | Zevor-cel (CT053) – BCMA CAR-T for R/R multiple myeloma,Autologous solid-tumor CAR-T (CT041, CT011, CT071, CT0590/CT0596),Autoimmune and B-cell malignancy pipeline (KJ-C2219, KJ-C2320, KJ-C2529), |
| CARTESIAN THERAPEUTICS, INC. | United States | Public Company | Descartes-08 (autoimmune and rare pediatric indications),Descartes-15 (multiple myeloma),Platform and other mRNA cell therapy programs/services, |
| LYELL IMMUNOPHARMA, INC. | United States | Public Company | Hematologic CAR T programs (ronde-cel and platform),Solid tumor CAR T programs (LYL273 and related),Platform technologies and enabling IP (c-Jun, NR4A3 KO, Epi-R, CD62L enrichment), |
JOHNSON & JOHNSON
Johnson & Johnson is a diversified healthcare company founded in 1886 and headquartered in the United States. With 138,200 employees, it operates as a public company serving global markets.
GILEAD SCIENCES, INC.
Gilead Sciences, Inc. is a United States-based biopharmaceutical company founded in 1987. The public company employs 17,000 people and focuses on developing innovative therapeutics.
BRISTOL-MYERS SQUIBB COMPANY
Bristol-Myers Squibb Company is a pharmaceutical company established in 1887 in the United States. As a public company with 32,500 employees, it develops and manufactures pharmaceutical products.
NOVARTIS AG
Novartis AG is a Swiss multinational pharmaceutical company founded in 1996. The public company employs 75,267 people and operates globally in the healthcare sector.
AUTOLUS THERAPEUTICS
Autolus Therapeutics is a United Kingdom-based biopharmaceutical company founded in 2014. The public company has 753 employees and focuses on cell therapy development.
JW (CAYMAN) THERAPEUTICS CO., LTD.
JW (Cayman) Therapeutics Co., Ltd. is a China-based pharmaceutical company founded in 2016. The public company employs 314 people and operates in the therapeutic development sector.
CARSGEN THERAPEUTICS HOLDINGS LIMITED
Carsgen Therapeutics Holdings Limited is a China-based biopharmaceutical company founded in 2014. The public company has 355 employees and specializes in cell therapy development.
CARTESIAN THERAPEUTICS, INC.
Cartesian Therapeutics, Inc. is a United States-based public biopharmaceutical company with 75 employees. The company specializes in cell therapy and therapeutic development.
LYELL IMMUNOPHARMA, INC.
Lyell Immunopharma, Inc. is a United States-based public immunotherapy company founded in 2018. The company has 161 employees and develops cell-based immunotherapies.
Reasons to Buy this Report
- Regional Market Sizing & Forecasts : Obtain precise market size data for Rest Of Europe ($22.1M in 2026, $33.3M in 2031) with detailed CAGR analysis to support strategic planning and investment decisions specific to the region.
- Competitive Landscape Intelligence : Understand market dynamics, key players, and competitive positioning within Rest Of Europe's CAR T-cell therapy sector to identify partnership and expansion opportunities.
- Growth Driver Analysis : Identify specific factors driving 8.5% CAGR in Rest Of Europe including healthcare infrastructure investments, regulatory changes, and reimbursement trends affecting market expansion.
- Country-Level Insights : Access granular data on individual Rest Of Europe markets to prioritize market entry strategies, resource allocation, and localized go-to-market approaches.
- Strategic Decision Support : Leverage comprehensive Rest Of Europe market analysis to inform product development, pricing strategies, and commercial planning for CAR T-cell therapy launches and expansions.
Frequently asked questions
What is the current market size of CAR T-cell therapy in Rest Of Europe?
Rest Of Europe's CAR T-cell therapy market was valued at $22.1 million in 2026 and is expected to grow to $33.3 million by 2031.
What is the projected growth rate for CAR T-cell therapy in Rest Of Europe?
Rest Of Europe's CAR T-cell therapy market is projected to grow at a compound annual growth rate (CAGR) of 8.5% from 2026 to 2031.
Why is Rest Of Europe's CAR T-cell therapy market growing slower than Western Europe?
Rest Of Europe faces challenges including lower healthcare spending, limited manufacturing capacity, and slower regulatory approval processes compared to Western European markets, though these barriers are gradually diminishing.
What factors are driving CAR T-cell therapy adoption in Rest Of Europe?
Rest Of Europe's market growth is driven by increasing oncology investments, expanding clinical trial networks, improving healthcare infrastructure, and rising patient awareness of advanced immunotherapy options.
Which countries in Rest Of Europe are leading CAR T-cell therapy adoption?
Rest Of Europe's adoption is concentrated in countries with stronger healthcare systems and research capabilities, though specific country-level data varies based on regulatory maturity and reimbursement policies.
RESEARCH METHODOLOGY
This study involved four major activities in estimating the current size of the CAR T-cell therapy market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. These findings, assumptions, and sizing were then validated with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. Following this, market breakdown and data triangulation procedures were used to estimate the market size of segments and subsegments.
Secondary Research
Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study. The secondary sources referred for this research study include publications from government sources, such as the National Center for Biotechnology Information (NCBI), National Institutes of Health (NIH), World Health Organization (WHO), United States Food and Drug Administration (US FDA), American Society of Gene & Cell Therapy (ASGCT), European Medicines Agency (EMA), Industry Association of Synthetic Biology (IASB), International Society for Cell & Gene Therapy (ISCT), National Center for Complementary and Integrative Health (NCCIH), BioPharm International, ScienceDirect, News Articles, Journals, Press Releases, Paid Databases, Expert Interviews, and MarketsandMarkets Analysis, among others. Secondary sources also included corporate and regulatory filings (such as annual reports, SEC filings, investor presentations, and financial statements); business magazines and research journals; press releases; and trade, business, and professional associations. These sources were also used to obtain key information about major players, global product revenues, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives. Secondary data was collected and analyzed to arrive at the overall size of the global CAR T-cell therapy market, which was validated through primary research.
Primary Research
In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among other experts, to obtain and verify the critical qualitative and quantitative information as well as assess future prospects of the market. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is a breakdown of the primary respondents:
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
The global size of the CAR T-cell therapy market was estimated through multiple approaches. A detailed market estimation approach was followed to estimate and validate the value of the market and other dependent submarkets. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
CAR T-Cell Therapy Market Size: Bottom-up Approach and Top-down Approach
Data Triangulation
After estimating the overall market size from the market size estimation process, the total market was split into several segments. To complete the overall market engineering process and arrive at the exact statistics for all segments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Market Definition
CAR T-cell therapy is a treatment method wherein a patient’s T-cells (a type of immune system cell) undergo modification in a laboratory to target and attack cancer cells effectively. Initially, T-cells are extracted from the patient’s bloodstream. Then the gene for a special receptor that binds to a specific protein on the patient’s cancer cells is added to the T cells in the laboratory. The special receptor is known as a chimeric antigen receptor (CAR). Following this modification process, the CAR T-cells are cultured and multiplied in large quantities. Finally, the amplified CAR T-cells are administered to the patient via infusion. This therapeutic approach is predominantly utilized in the management of specific blood cancers, and ongoing research is exploring its potential applications in treating other forms of cancer. The CAR T-Cell therapy market includes approved and pipeline CAR T-cell products for therapeutic purposes.
Key Stakeholders
- Pharmaceutical Companies
- Biotechnology Companies
- Clinical Research Organizations (CROs)
- Regulatory Authorities
- Healthcare Providers
- Patients and Patient Advocacy Groups
- Investors and Venture Capital Firms
- Research & Development Companies
- Research Laboratories & Academic Institutes.
- Market Research & Consulting Firms
Report Objectives
- To define, describe, and forecast the CAR T-cell therapy market by value for product, target, indication, demographic, end user, and region
- To define, describe, and forecast the CAR T-cell therapy market by volume for the product segment at the global level
- To provide detailed information regarding the major drivers, restraints, opportunities, and challenges, influencing the market growth
- To analyze the micromarkets with respect to individual growth trends, prospects, and contributions to the overall CAR T-cell therapy market
- To analyze the opportunities for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of the market segments with respect to five regions: North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
- To profile the key players and analyze their market shares and core competencies
- To track and analyze competitive developments, such as product launches, partnerships, agreements, collaborations, and expansions
- To benchmark players within the market using the proprietary “Company Evaluation Matrix” framework, which analyzes market players on various parameters within the broad categories of business and product excellence strategy
- To provide an overview of the market with specialized analysis such as trends/disruptions impacting customers’ business, pricing analysis, value/ supply chain analysis,ecosystem analysis, technology analysis, patent analysis, key conferences & events 2026-2027, regulatory landscape, Porter’s five forces analysis, key stakeholders and buying criteria, and investment and funding scenario
Available customizations:
- With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:
Geographic Analysis
- Further breakdown of the Rest of Europe CAR T-cell therapy market, by country
- Further breakdown of the Rest of Asia Pacific CAR T-cell therapy market, by count
Company Information
- Detailed analysis and profiling of additional market players (up to five
Segment Analysis
- Cross-segment analysis
Get the Full CAR T-Cell Therapy Market Report
Full forecast, segment splits, and company analysis for all CAR T-Cell Therapy Market.
- US CAR T-Cell Therapy Market
- Canada CAR T-Cell Therapy Market
- Germany CAR T-Cell Therapy Market
- UK CAR T-Cell Therapy Market
- France CAR T-Cell Therapy Market
- Italy CAR T-Cell Therapy Market
- Spain CAR T-Cell Therapy Market
- China CAR T-Cell Therapy Market
- Japan CAR T-Cell Therapy Market
- India CAR T-Cell Therapy Market
- Australia CAR T-Cell Therapy Market
- South Korea CAR T-Cell Therapy Market
- Brazil CAR T-Cell Therapy Market
- UAE CAR T-Cell Therapy Market
- Rest Of Asia Pacific CAR T-Cell Therapy Market
- Rest Of Latin America CAR T-Cell Therapy Market
- GCC Countries CAR T-Cell Therapy Market
- Rest Of Middle East CAR T-Cell Therapy Market
- Kingdom Of Saudi Arabia CAR T-Cell Therapy Market
- Rest Of GCC Countries CAR T-Cell Therapy Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report